BioCentury
ARTICLE | Finance

Market recalibrates Biogen’s valuation as aducanumab filing is delayed

Roller-coaster ride for Alzheimer’s therapy continues as investors reassess its chances for success submission.

April 23, 2020 2:17 AM UTC
Updated on Apr 23, 2020 at 2:27 AM UTC

Biogen’s aducanumab roller-coaster ride continued Wednesday as investors reassessed the risk for the Alzheimer’s therapy following a roughly six-month delay for the company’s BLA submission.

Biogen Inc. (NASDAQ:BIIB) disclosed Wednesday plans to push back an FDA submission date for aducanumab from early this year to 3Q20, triggering a $5.4 billion loss in market cap. The stock fell $31 to $298.01 on the day. ...

BCIQ Company Profiles

Biogen Inc.

BCIQ Target Profiles

Beta amyloid